FSD Pharma Inc. Files 6-K, Announces Exclusive Agreement
Ticker: QNTM · Form: 6-K · Filed: Jun 13, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, agreement
TL;DR
FSD Pharma signs exclusive deal, files 6-K. Details in press release.
AI Summary
FSD Pharma Inc. filed a Form 6-K on June 13, 2024, reporting on its activities for the month of June 2024. The filing includes a press release announcing FSD Pharma's entry into an exclusive agreement. Nathan Coyle, Chief Financial Officer, signed the report on June 12, 2024.
Why It Matters
This filing indicates FSD Pharma Inc. is pursuing new strategic partnerships or business development opportunities through an exclusive agreement, which could impact its future growth and market position.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the 'exclusive agreement' mentioned could represent significant strategic shifts or financial commitments for FSD Pharma, introducing uncertainty.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- June 13, 2024 (date) — Filing Date
- June 12, 2024 (date) — Report Signing Date
FAQ
What is the nature of the exclusive agreement FSD Pharma Inc. has entered into?
The filing mentions FSD Pharma Inc. has entered into an exclusive agreement, with details likely contained within the referenced press release (Exhibit 99.1).
Who signed the Form 6-K filing on behalf of FSD Pharma Inc.?
The Form 6-K was signed by Nathan Coyle, Chief Financial Officer, on June 12, 2024.
What is the Commission File Number for FSD Pharma Inc.'s filing?
The Commission File Number for this filing is 001-39152.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on June 13, 2024.
Does FSD Pharma Inc. file annual reports under Form 20-F or 40-F?
FSD Pharma Inc. indicated it files annual reports under Form 20-F.
Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-06-13 07:31:31
Filing Documents
- fsd_6k.htm (6-K) — 8KB
- fsd_ex991.htm (EX-99.1) — 20KB
- fsd_ex991img2.jpg (GRAPHIC) — 6KB
- 0001654954-24-007685.txt ( ) — 38KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: June 12, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3